Ayurvedic Treatments for Interstitial Lung Disease

Interstitial lung disease (ILD) is not a single condition — it is an umbrella term for a group of over 200 disorders that cause progressive scarring (fibrosis) and inflammation of the lung tissue, specifically the interstitium. The interstitium is the thin, delicate tissue network that supports the tiny air sacs (alveoli) in your lungs. When this tissue becomes damaged, it thickens and stiffens, making it increasingly difficult for oxygen to pass into the bloodstream. The result is chronic, often worsening breathlessness that can significantly impact quality of life.

Also referred to as diffuse parenchymal lung disease (DPLD), ILD affected an estimated 1.9 million people globally in 2015 and was linked to approximately 122,000 deaths that year. While some forms of ILD are reversible when caught early, others — most notably idiopathic pulmonary fibrosis (IPF) — are progressive and carry a median survival of just 2 to 5 years from diagnosis. Understanding the types, causes, stages, and available treatments is essential for anyone navigating this complex family of diseases.

What Is Interstitial Lung Disease?

Interstitial lung disease describes any disorder in which the lung parenchyma — the functional tissue responsible for gas exchange — becomes inflamed, scarred, or both. Unlike obstructive lung diseases such as COPD or asthma, where airflow is blocked, ILD causes a restrictive pattern: the lungs cannot fully expand, and their capacity to transfer oxygen to the blood is reduced.

How Does ILD Differ from COPD and Asthma?

This distinction matters because it affects everything from diagnosis to treatment. In obstructive diseases, you struggle to push air out. In ILD (a restrictive disease), the lungs become stiff and cannot fill in. Pulmonary function tests (PFTs) clearly differentiate these patterns — ILD shows reduced total lung capacity (TLC) and forced vital capacity (FVC), while the FEV1/FVC ratio usually remains normal or is even elevated.

Some ILD subtypes, like sarcoidosis, can show mixed obstructive-restrictive features, which sometimes leads to misdiagnosis as COPD. This is why accurate diagnostic workup is critical.

Pathophysiology: From Inflammation to Fibrosis

The underlying process in most ILDs follows a recognizable cascade:

• 1.Initial trigger — environmental exposure, autoimmune attack, drug reaction, or unknown cause
• 2.Inflammatory response — immune cells infiltrate the interstitium, causing alveolitis
• 3.Fibroblast activation — fibroblastic foci develop, producing excessive collagen
• 4.Progressive fibrosis — normal lung architecture is replaced by dense scar tissue
• 5.Impaired gas exchange — thickened interstitium prevents efficient oxygen transfer

In idiopathic pulmonary fibrosis (IPF), the histopathological pattern is called usual interstitial pneumonia (UIP), characterized by patchy fibrosis, honeycombing, and fibroblastic foci. Other patterns include nonspecific interstitial pneumonia (NSIP), organizing pneumonia (OP), and diffuse alveolar damage (DAD). Each pattern correlates with a different prognosis and treatment approach.

What Are the Types and Examples of Interstitial Lung Disease?

With over 200 recognized subtypes, ILD classification can feel overwhelming. The most practical way to organize them is by whether the cause is known or unknown (idiopathic).

Known Causes

Idiopathic Interstitial Pneumonias (IIPs)

Other Important ILDs

• Sarcoidosis — granulomatous disease that can affect multiple organs; relatively common in young adults
• Lymphangioleiomyomatosis (LAM) — rare, primarily affects women of childbearing age
• Pulmonary Langerhans cell histiocytosis — strongly associated with cigarette smoking
• Eosinophilic pneumonia — characterized by eosinophil infiltration in the lungs

Interstitial Lung Disease in Children (ChILD)

Pediatric ILD, collectively known as ChILD (Children's Interstitial Lung Disease), represents a distinct group of conditions that differ from adult ILD. These include surfactant protein gene mutations (SP-B, SP-C, ABCA3 deficiency), neuroendocrine cell hyperplasia of infancy (NEHI), and diffuse developmental disorders of the lung. Genetic testing plays a crucial role in diagnosing these conditions, as many are inherited. ChILD is rare but often severe, requiring specialized pediatric pulmonology care.

What Causes ILD and Who Is at Risk?

Known Causes of ILD

The causes of interstitial lung disease span a wide spectrum:

• Autoimmune and connective tissue diseases — rheumatoid arthritis, systemic sclerosis (scleroderma), polymyositis/dermatomyositis, mixed connective tissue disease, systemic lupus erythematosus
• Occupational and environmental exposures — chronic inhalation of asbestos, silica dust, coal dust, hard metal dust, grain dust, or animal proteins
• Medications — certain chemotherapy drugs (bleomycin), cardiac drugs (amiodarone), antibiotics (nitrofurantoin), and immunotherapy agents
• Radiation therapy — particularly to the chest, as in breast or lung cancer treatment
• Infections — including COVID-19, which has emerged as a significant cause of post-infectious lung fibrosis

In roughly 30–40% of cases, no identifiable cause is found, and the disease is classified as idiopathic.

Risk Factors

• Age — most forms of ILD occur in adults over 40; IPF typically presents between ages 60 and 70
• Smoking — a major risk factor for IPF, DIP, RB-ILD, and pulmonary Langerhans cell histiocytosis
• Occupational exposure — mining, farming, construction, textile work, and bird keeping
• Family history — familial pulmonary fibrosis accounts for 5–20% of IPF cases; mutations in telomerase genes (TERT, TERC) and MUC5B have been identified
• Gastroesophageal reflux disease (GERD) — chronic microaspiration may worsen or contribute to ILD progression; treatment of GERD is now considered part of comprehensive ILD management
• Gender — IPF is more common in men; LAM occurs almost exclusively in women

Symptoms of Interstitial Lung Disease

Early Symptoms

The hallmark symptom of ILD is progressive dyspnea (shortness of breath), initially noticeable only during physical activity — climbing stairs, walking uphill, or exercising. Many patients attribute this to aging or being "out of shape," which contributes to diagnostic delay.

Other early symptoms include:

• Persistent dry, nonproductive cough
• Mild fatigue and reduced exercise tolerance
• A general feeling of chest tightness or discomfort

Advanced Symptoms

As the disease progresses, symptoms become more pronounced:

• Breathlessness at rest
• Digital clubbing — widening and rounding of the fingertips and nails, seen in up to 50% of IPF patients
• Unintentional weight loss
• Velcro crackles — fine, dry crackles heard through a stethoscope at the lung bases, resembling the sound of Velcro being pulled apart. This is a classic auscultatory finding
• Cyanosis (bluish discoloration of the lips or fingertips) due to low blood oxygen levels
• Signs of right-sided heart failure in advanced cases (peripheral edema, jugular venous distention)

The insidious onset of symptoms means that many patients are not diagnosed until significant lung damage has already occurred. Studies suggest the average delay from symptom onset to diagnosis is 1 to 2 years.

Stages of Interstitial Lung Disease

One of the notable gaps in existing online resources is a clear staging framework for ILD. While there is no single universally adopted staging system (unlike cancer staging), several clinical tools help quantify disease severity and predict prognosis.

GAP Index and Staging System

The GAP index (Gender, Age, Physiology) is the most widely used prognostic model for IPF:

Scoring: Male = 1 point; Age 61–65 = 1, >65 = 2; FVC ≥75% = 0, 50–75% = 1, <50% = 2; DLCO >55% = 0, 36–55% = 1, ≤35% = 2, cannot perform = 3.

PFT-Based Severity Grading

Pulmonary function tests provide another way to categorize disease severity:

• Mild — FVC >70% predicted, DLCO >55% predicted
• Moderate — FVC 50–70%, DLCO 36–55%
• Severe — FVC <50%, DLCO ≤35%

HRCT-Based Progression

High-resolution CT patterns also inform staging:

• Early — ground-glass opacities, minimal or no fibrosis
• Intermediate — reticular markings with traction bronchiectasis
• Advanced — established honeycombing, architectural distortion, volume loss

A decline in FVC of ≥10% or DLCO of ≥15% over 6–12 months is considered clinically significant progression, regardless of the starting stage.

How Is Interstitial Lung Disease Diagnosed?

Diagnosing ILD requires a systematic, stepwise approach — and often a multidisciplinary discussion (MDD) involving pulmonologists, radiologists, pathologists, and rheumatologists.

Step-by-Step Diagnostic Algorithm

Step 1: Clinical Suspicion

History of progressive dyspnea + dry cough + velcro crackles on examination → suspect ILD

Step 2: Initial Workup

• Chest X-ray — may show bilateral reticular or reticulonodular opacities, but can be normal in early disease
• Blood tests — ANA, RF, anti-CCP, myositis panel, ESR/CRP to screen for connective tissue disease; KL-6 and SP-D as potential biomarkers
• Pulmonary function tests — restrictive pattern (reduced FVC, reduced TLC, reduced DLCO with preserved FEV1/FVC ratio)

Step 3: High-Resolution CT (HRCT)

• This is the single most important diagnostic imaging tool.
• HRCT patterns help narrow the differential:
• UIP pattern (peripheral, basal honeycombing + traction bronchiectasis) → probable IPF
• NSIP pattern (bilateral ground-glass with subpleural sparing)
• HP pattern (upper/mid-zone predominance, mosaic attenuation, air trapping)

Step 4: Multidisciplinary Discussion (MDD)

A team of specialists reviews clinical, radiological, and laboratory data to reach a working diagnosis. Research shows MDD improves diagnostic accuracy by 10–20% compared to individual physician assessment.

Step 5: Tissue Sampling (if needed)

If the diagnosis remains uncertain after HRCT and clinical data:

• Bronchoalveolar lavage (BAL) — cellular analysis can suggest HP, eosinophilic pneumonia, or infection
• Transbronchial cryobiopsy — a newer, less invasive alternative to surgical biopsy that provides larger tissue samples with lower complication rates and comparable diagnostic yield
• Surgical lung biopsy (VATS) — the gold standard for histopathological diagnosis but carries a 1–2% mortality risk in ILD patients

Interstitial Lung Disease Radiology: Key HRCT Patterns

How Is Interstitial Lung Disease Treated?

Treatment for ILD depends heavily on the specific subtype, the stage of the disease, and whether the underlying cause is identifiable. There is no one-size-fits-all approach.

Medications

Anti-inflammatory and Immunosuppressive Therapy:

• Corticosteroids (prednisone) — first-line for sarcoidosis, COP, CTD-ILD, and HP; NOT effective for IPF
• Mycophenolate mofetil — commonly used in CTD-ILD, particularly scleroderma-related ILD
• Azathioprine — used in combination therapy for some autoimmune-related ILDs
• Cyclophosphamide — reserved for severe or rapidly progressive CTD-ILD

Antifibrotic Therapy (for IPF and progressive fibrosing ILD):

• Pirfenidone — slows FVC decline by approximately 50% vs placebo (ASCEND trial, 2014)
• Nintedanib — similarly reduces the rate of lung function decline; also approved for progressive fibrosing ILD beyond IPF (INBUILD trial, 2019) and systemic sclerosis-ILD (SENSCIS trial)

Biologic and Novel Agents:

• Rituximab — showing promise in refractory CTD-ILD and some cases of IPF
• Tocilizumab — IL-6 inhibitor being studied in systemic sclerosis-ILD
• Nerandomilast — a novel PDE4B inhibitor in late-stage clinical trials for IPF
• Autotaxin inhibitors, inhaled therapies, and cell-based therapies — currently in various phases of clinical trials, representing the next frontier in ILD treatment

Non-Pharmacological Treatment

• Supplemental oxygen therapy — for patients with resting or exertional hypoxemia (SpO2 <88%)
• Pulmonary rehabilitation — structured exercise and education programs that improve exercise capacity, reduce dyspnea, and enhance quality of life
• Lung transplantation — the only treatment that can significantly extend life in end-stage ILD; referral should be considered early in progressive cases
• Vaccination — influenza and pneumococcal vaccines are strongly recommended to prevent respiratory infections
• GERD management — proton pump inhibitors may help reduce microaspiration-related lung injury

Acute Exacerbations of ILD

Acute exacerbations represent sudden, clinically significant deterioration over days to weeks. They are most feared in IPF, where they carry a mortality rate of 50–80%.

Triggers include respiratory infections, aspiration, air pollution, and sometimes no identifiable cause. Diagnosis requires exclusion of heart failure, pulmonary embolism, and infection. Treatment typically involves high-dose corticosteroids, supportive oxygen, and sometimes mechanical ventilation, though evidence for specific therapies remains limited.

Recognizing acute exacerbations early is crucial — any sudden worsening of dyspnea in an ILD patient warrants urgent medical evaluation.

What Can You Expect? Prognosis and Life Expectancy

Can You Survive Interstitial Lung Disease?

The answer depends entirely on the specific subtype and how early it is diagnosed.

• IPF — median survival 2–5 years from diagnosis; antifibrotic therapy can slow progression but does not reverse fibrosis
• NSIP — 5-year survival of 70–90%, especially the cellular variant
• COP — often fully reversible with corticosteroids; excellent prognosis
• Sarcoidosis — spontaneous remission occurs in about two-thirds of cases; only a minority develop progressive fibrosis
• CTD-ILD — varies widely; scleroderma-ILD carries a worse prognosis than RA-ILD
• HP — if the offending antigen is identified and removed, significant improvement or stabilization is possible

Approximately 30–40% of ILD patients develop progressive pulmonary fibrosis regardless of initial subtype.

Complications

• Pulmonary hypertension — develops in 30–50% of advanced ILD cases; significantly worsens prognosis
• Respiratory failure — the leading cause of death in ILD
• Lung cancer — IPF increases lung cancer risk 7-fold
• Pneumothorax — collapsed lung due to subpleural cyst rupture
• Recurrent respiratory infections — impaired lung defense mechanisms

Living with ILD: Lifestyle, Mental Health & Ongoing Management

Lifestyle Modifications

• Quit smoking immediately — this is non-negotiable for any ILD patient
• Stay physically active — regular, gentle exercise (walking, yoga, breathing exercises) maintains conditioning and reduces deconditioning
• Eat a balanced diet — anti-inflammatory foods, adequate protein, and maintaining a healthy weight help overall respiratory function
• Avoid triggers — known environmental or occupational exposures must be eliminated
• Pulse oximetry at home — monitoring oxygen levels helps detect early deterioration

Mental Health and Psychological Support

Living with a chronic, progressive lung disease takes an enormous psychological toll. Studies show that 30–50% of ILD patients experience clinically significant anxiety or depression. Chronic hypoxemia can also contribute to cognitive impairment and sleep disturbances.

Patients should be screened regularly for mental health concerns. Psychological counseling, support groups (both in-person and online), and in some cases antidepressant or anxiolytic medication can meaningfully improve quality of life. This is an area that remains underserved in most ILD management programs.

Palliative Care and End-of-Life Planning

Palliative care is NOT the same as end-of-life care — it can and should be integrated early in the disease course to manage symptoms like refractory dyspnea, chronic cough, fatigue, and anxiety. Opioids in low doses have evidence supporting their use for managing breathlessness that doesn't respond to other treatments.

Advance care planning — discussing preferences for mechanical ventilation, ICU care, and resuscitation — should be initiated early, ideally when the patient is stable enough to participate in these conversations. Unfortunately, this aspect of ILD care is rarely addressed systematically.

The Role of Telemedicine and Remote Monitoring

Post-pandemic, telemedicine has become an increasingly important tool in ILD management. Home spirometry devices can track FVC trends between clinic visits. Wearable pulse oximeters enable early detection of desaturation. Virtual pulmonary rehabilitation programs have shown comparable outcomes to in-person programs in early studies. For patients in rural areas or those with limited mobility, telehealth consultations with ILD specialists can reduce the burden of travel and improve access to expert care.

ILD and COVID-19: Post-COVID Pulmonary Fibrosis

COVID-19 has emerged as a recognizable cause of new-onset ILD. Post-COVID pulmonary fibrosis can develop even after mild-to-moderate infection, though it's more common following severe disease or prolonged mechanical ventilation.

Key points:

• An estimated 2–6% of hospitalized COVID-19 patients develop persistent fibrotic lung changes at 12 months
• Post-COVID ILD typically shows an organizing pneumonia or NSIP pattern on HRCT, rather than the UIP pattern seen in IPF
• Most post-COVID fibrotic changes stabilize or partially improve over 12–18 months, unlike classical IPF which is relentlessly progressive
• Antifibrotic therapy (nintedanib, pirfenidone) is being studied in post-COVID fibrosis, but evidence remains preliminary
• Patients with pre-existing ILD who contract COVID-19 face significantly higher mortality

Ayurvedic Perspectives on ILD Management

In the Indian context, many patients explore Ayurvedic approaches alongside conventional treatment. Ayurveda views ILD through the lens of Pranavaha Srotas (respiratory channels) vitiation and Kapha-Vata imbalance. Therapies such as Vasaka (Adhatoda vasica), Kantakari (Solanum xanthocarpum), and Panchakarma detoxification procedures like Vamana and Virechana are traditionally used to support respiratory health.

While these approaches may offer symptomatic relief and improved quality of life, they should be used as complementary — not alternative — therapy. Patients must continue evidence-based medical treatments and discuss any Ayurvedic medications with their pulmonologist to avoid harmful interactions.

Frequently Asked Questions

Can ILD Be Prevented?

While idiopathic forms cannot be prevented, many ILDs are avoidable. Eliminating occupational exposure (using proper respiratory protection), quitting smoking, and promptly treating autoimmune diseases reduces risk significantly. Regular monitoring of patients on high-risk medications (amiodarone, methotrexate, bleomycin) with periodic PFTs can catch drug-induced ILD early.

What Is the Most Common Interstitial Lung Disease?

IPF is the most common idiopathic interstitial pneumonia, accounting for over 30% of all ILD cases. Among ILDs with known causes, connective tissue disease-related ILD and hypersensitivity pneumonitis are the most frequent.

When Should I See My Healthcare Provider?

Seek medical attention if you experience persistent shortness of breath (especially if worsening over weeks to months), a dry cough lasting more than 8 weeks, unexplained fatigue, or if you have known risk factors like autoimmune disease or occupational dust exposure. Any sudden worsening of breathlessness in a diagnosed ILD patient requires urgent evaluation.

What's the Life Expectancy for Interstitial Lung Disease?

• Life expectancy varies dramatically by subtype. IPF carries a median survival of 2–5 years, but some patients with COP or cellular NSIP achieve full remission.
• Early diagnosis and appropriate treatment — whether antifibrotic, immunosuppressive, or transplantation — can significantly alter the trajectory of the disease.

Is Interstitial Lung Disease the Same as Pulmonary Fibrosis?

Not exactly. Pulmonary fibrosis (lung scarring) is a feature of many ILDs, but not all ILDs involve fibrosis. Some, like cellular NSIP or COP, are primarily inflammatory and potentially reversible. "Pulmonary fibrosis" is sometimes used interchangeably with IPF in common language, but medically they are distinct concepts.

Take the Next Step

If you or a loved one is experiencing unexplained breathlessness or a persistent dry cough, don't wait. Early diagnosis of interstitial lung disease can make a real difference in outcomes. Speak with a pulmonologist, request an HRCT if your chest X-ray is inconclusive, and ask about multidisciplinary evaluation. For those already diagnosed, stay engaged with your treatment plan, attend pulmonary rehabilitation, monitor your oxygen levels at home, and don't neglect your mental health.

Knowledge is power — and in ILD, timely action saves lungs.

Scientific Sources

1. Occupational interstitial lung diseases — Spagnolo P et al., 2023, Journal of internal medicine
2. Global burden of chronic respiratory diseases and risk factors, 1990-2019: an update from the Global Burden of Disease Study 2019 — GBD 2019 Chronic Respiratory Diseases Collaborators, 2023, EClinicalMedicine
3. Telerehabilitation for chronic respiratory disease — Cox NS et al., 2021, The Cochrane database of systematic reviews
4. Senescent endothelial cell-derived Galectin 3 promotes silicosis through endothelial-fibroblast and endothelial-macrophage crosstalk — Cheng D et al., 2025, Journal of hazardous materials
5. The prevalence and risk factors of rheumatoid arthritis-associated interstitial lung disease: a systematic review and meta-analysis — Wang HF et al., 2024, Annals of medicine
6. Diagnosis and Evaluation of Hypersensitivity Pneumonitis: CHEST Guideline and Expert Panel Report — Fernández Pérez ER et al., 2021, Chest
7. New horizons in systemic sclerosis treatment: advances and emerging therapies in 2025 — Sieiro Santos C et al., 2025, RMD open
8. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study — Ren Z et al., 2021, The Lancet. Oncology
9. Global, regional, and national burden of chronic respiratory diseases and impact of the COVID-19 pandemic, 1990-2023: a Global Burden of Disease study — Oh J et al., 2026, Nature medicine
10. Current Understanding of Pulmonary Fibrosis: Pathogenesis, Diagnosis, and Therapeutic Approaches — Cui D et al., 2025, Canadian respiratory journal
11. Antibody-drug conjugate components in association with the incidence of ADC-related interstitial lung disease: A systematic review and meta-analysis — Shao T et al., 2025, Lung cancer (Amsterdam, Netherlands)
12. Self-assembled vectors derived from Aster tataricus L.f. mitigate bleomycin-induced pulmonary fibrosis in mice — Meng Y et al., 2025, Materials today. Bio
13. Therapeutic potential of traditional Chinese medicine for interstitial lung disease — Zhou YM et al., 2024, Journal of ethnopharmacology
14. Astragaloside IV protects against lung injury and pulmonary fibrosis in COPD by targeting GTP-GDP domain of RAS and downregulating the RAS/RAF/FoxO signaling pathway — Zhang M et al., 2023, Phytomedicine : international journal of phytotherapy and phytopharmacology
15. Treatment for systemic sclerosis-associated interstitial lung disease — Roofeh D et al., 2021, Current opinion in rheumatology
16. Pulmonary manifestations of polymyositis/dermatomyositis — Hallowell RW et al., 2014, Seminars in respiratory and critical care medicine
17. Licochalcone B attenuates pulmonary fibrosis via inhibiting ZBP1-dependent PANoptosis — Ren H et al., 2025, Journal of ethnopharmacology
18. Evaluation and management of rheumatoid arthritis-associated interstitial lung disease — Ito Y et al., 2025, Respiratory investigation
19. Shifting Paradigms in the Management of Pulmonary Hypertension — Pradhan A et al., 2024, European cardiology
20. Research progress on complications of rheumatoid arthritis — Zeng H et al., 2025, Frontiers in immunology